In workers’ comp pharmacy management, opioids often get the lion’s share of attention, and for good reason. Continue reading.
We’re back with the second part of our exclusive interview with Peter Rousmaniere in which he discusses how current trends will impact the future of the industry and gives us a preview of what he plans to do next after his retirement from workers’ comp. Here’s part 2.
Mitchell's all-makes scan tools from Bosch offer full access to FCA secure vehicle networks and dramatic speed improvements for pre- and post-scanning.
In September 2019, the U.S. Food and Drug Administration (FDA) reported the discovery of low levels of an impurity in brand, generic, and over- the-counter (OTC) versions of a popular heartburn medication, Zantac® (Ranitidine HCl) 1, prompting a flurry of manufacturer recalls, national distribution halts, and product removals from retail pharmacy shelves. Ranitidine is an H2 (Histamine-2) blocker approved as a prescription medicine for treatment and prevention of GI ulcers and gastroesophageal reflux disease (GERD). OTC versions are approved for relief of acid indigestion and sour stomach. H2 blockers (like Tagamet, Pepcid, and Zantac) act by reducing the amount of acid produced by cells lining the stomach.
When you think of industry icons in workers’ comp, Peter Rousmaniere is among the select few at the top of the list. For more than 30 years, Peter has been a major influencer in workers’ comp, especially over the past couple of decades as a popular columnist. Last month, Peter announced his well-deserved retirement, so we asked him to join us on Inside Workers’ Comp to talk about his celebrated career and offer insights on the industry. The conversation was so profound that we made it into a two-parter. Here’s Part 1.
The impact of emotion AI on “humane” claims automation; the complexities of windshield repair; and actionable insights for maximizing value of claims data and analytics.
The state of Ohio, among the hardest hit in the nation for opioid overdose deaths, has undertaken a number of measures to meet the crisis as it has evolved. A review of opioid use in the injured worker population, completed in 2011, revealed an alarming number (73%) were filling opioid prescriptions.1 A closed formulary, expanded access to antidote products (naloxone), and opioid focused prescribing guidelines have all followed since and have contributed to some reductions in prescribing and the prevalence of opioid use.